After several rejections over 20-plus years, Fabre-Kramer Pharmaceuticals has secured the FDA’s approval for its major depressive disorder drug gepirone hydrochloride, now marketed under the brand name Exxua.
https://www.pharmalive.com/wp-content/uploads/2023/01/depression.jpeg350625BioSpacehttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngBioSpace2023-09-29 09:35:212023-09-29 09:54:16Fabre-Kramer finally gets FDA approval for MDD drug after decades-long quest
